The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized...

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Trials

Background:

• Previous trials suggested fluvoxamine benefits patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
• This study investigated fluvoxamine's efficacy in preventing clinical deterioration in high-risk COVID-19 outpatients.

Purpose of the Study:

• To evaluate if fluvoxamine prevents clinical deterioration in non-hospitalized COVID-19 patients.
• To assess the safety and efficacy of fluvoxamine in managing mild to moderate COVID-19.

Main Methods:

• A randomized, double-blind, placebo-controlled, remote trial involving 547 participants.
• Participants received either fluvoxamine or placebo for 15 days, starting within 7 days of symptom onset.
• Primary outcome was clinical deterioration within 15 days, defined by shortness of breath and low oxygen saturation.

Main Results:

• Clinical deterioration occurred in 4.8% of the fluvoxamine group and 5.5% of the placebo group.
• The trial was stopped early for futility due to lower-than-predicted event rates and declining participant accrual.
• No statistically significant difference in clinical deterioration was observed between the fluvoxamine and placebo groups.

Conclusions:

• Fluvoxamine was not found to be efficacious in preventing clinical deterioration in unvaccinated outpatients with symptomatic COVID-19.
• The trial was underpowered to detect a significant effect due to low primary outcome rates.
• Further research may be needed to explore fluvoxamine's role in specific patient populations or earlier disease stages.